KLRG1 and neoplasm: On the other hand, metformin combination with C-REV does not decrease terminally differentiated CD103+ KLRG-1+ T regulatory cells in both the injected and contralateral tumor sides compared to the single-treated groups in bilateral Pan02 tumor model [40].